Billboards for Innovent Biologics and Meituan appeared in a Shanghai metro station on July 6 while companies including Eli Lilly compete in the once-weekly GLP-1 injection market. China’s National Health Commission projects that overweight or obese adults could exceed 65 percent of the population by 2030. Local rules bar direct prescription-drug advertising, prompting indirect promotions on transit and e-commerce platforms.